CAR-T Therapy May Cost Less Than Stem Cell Transplants Beyond the Price Tag, German Data Suggest

Chimeric antigen receptor T-cell therapy, better known as CAR-T, has been one of the most celebrated breakthroughs in modern cancer medicine. By genetically reprogramming a patient’s own immune cells to hunt and destroy malignant B cells, the therapy has reshaped the outlook for people with diffuse large B-cell lymphoma, an aggressive cancer of the lymphatic system that often resists conventional chemotherapy. Yet the technology has also carried a daunting reputation for expense, with drug acquisition costs that far exceed those of the traditional alternative, autologous stem cell transplantation. A new German study now argues that this headline price tells only part of the story, and that when the full economic footprint of treatment is measured, the gap between the two approaches may be narrower than widely assumed.

The research, published in the Journal of Cancer Research and Clinical Oncology, was conducted by a team led by Ann-Cathrine Froitzheim and Melina Sophie Kurte, who share first authorship, together with colleagues from the University of Duisburg-Essen, the VITIS Healthcare Group in Cologne, the DGDA-Institute in Hamburg, and the University of Cologne. Their central question was deceptively simple: what does it actually cost the German health system to deliver CAR-T therapy compared with autologous stem cell transplantation, once the price of the drug itself is set aside? Most economic evaluations of CAR-T have concentrated almost exclusively on the acquisition cost of the engineered cell product, leaving administration, hospitalization, and follow-up care largely unexamined. Those overlooked components, the authors contend, are essential for reimbursement decisions that affect real patients.

To answer the question, the investigators designed a two-step analysis drawing on two complementary German data sources. The first step used billing data from the statutory health insurance system, the public insurance scheme that covers the vast majority of the German population. The dataset represented approximately five million insured individuals, equivalent to roughly eight percent of all statutory health insurance members, and covered the years 2020 through 2022. Because the records were analyzed longitudinally, the researchers could track each patient’s costs over time rather than taking a single snapshot. The second step shifted perspective to the hospital level, using a cross-sectional analysis of all German inpatient cases recorded between 2020 and 2023, a dataset encompassing around seventeen million hospital admissions per year.

A key methodological choice shaped the entire analysis. The team divided costs into two categories: an initial regime, which captured every service associated with treatment except the acquisition cost of the CAR-T drug itself, and a following regime, which captured the costs of care that came after the initial treatment phase. This structure allowed the researchers to isolate the delivery and downstream costs that are usually invisible in headline price comparisons. In the insurance data cohort, the study included twelve patients who received CAR-T therapy and fifty-nine patients who underwent autologous stem cell transplantation, a stem cell transplant in which the patient’s own cells are harvested and reinfused after high-dose chemotherapy.

The findings from the initial regime were revealing. Median costs per patient during this phase amounted to 61,703 euros for CAR-T recipients compared with 55,802 euros for transplant recipients, meaning the cellular therapy carried a modestly higher upfront burden of delivery-related expenses. This is consistent with the intensive nature of CAR-T treatment, which requires leukapheresis to collect the patient’s T cells, specialized manufacturing, lymphodepleting chemotherapy before infusion, and close monitoring for potentially dangerous immune reactions. However, the picture reversed in the following regime. Here, CAR-T patients accumulated median costs of 44,832 euros, while transplant patients cost 69,453 euros, a difference of nearly 25,000 euros per patient in favor of the engineered cell therapy.

The safety profiles observed in the billing data help explain some of these downstream differences. The most frequently reported adverse events of any grade differed notably between the two groups. Among CAR-T patients, B-cell aplasia or neutropenia, conditions in which antibody-producing B cells or infection-fighting neutrophils are depleted, occurred in 77 percent of cases, compared with 64 percent of transplant patients. Thrombocytopenia, a shortage of platelets that raises bleeding risk, affected 38 percent of CAR-T recipients but 64 percent of transplant recipients. These patterns suggest that the two therapies impose different kinds of immunological and hematological stress on patients, which in turn translates into different patterns of hospitalization, supportive care, and resource use in the months following treatment.

The second step of the analysis, drawing on the nationwide inpatient database, provided an even starker contrast. The researchers identified 1,229 CAR-T hospitalizations and 2,239 autologous stem cell transplant hospitalizations between 2020 and 2023. The average length of stay was remarkably similar between the two groups, at 27.3 days for CAR-T and 27.8 days for transplantation, indicating that both therapies demand comparable inpatient resources in terms of time. Yet the average inpatient costs diverged dramatically: 13,991 euros per CAR-T admission versus 29,432 euros per transplant admission, meaning each CAR-T hospitalization cost roughly half as much as a transplant admission despite the similar duration of stay.

Taken together, the two analyses sketch an economic profile of CAR-T therapy that departs from conventional wisdom. The technology is undeniably expensive to acquire, but the costs of actually administering it and caring for patients afterward appear to be lower than those associated with autologous stem cell transplantation, both in the insurance billing data and in the nationwide hospital statistics. The authors emphasize that their analysis deliberately focused on administration-related and subsequent treatment costs, excluding drug acquisition costs, in order to characterize the economic burden that extends beyond drug pricing. This framing matters for health policy, because reimbursement systems that focus narrowly on the sticker price of a therapy may systematically underestimate the total resources a treatment pathway consumes.

The study also illustrates the growing power of real-world data in health economics. Rather than relying on modeled projections or clinical trial populations, the researchers mined routine billing records and national hospital statistics, capturing how these therapies are actually delivered across the German health system. Such real-world evidence is increasingly valued by regulators and payers because it reflects the complexities of everyday clinical practice, including comorbidities, treatment variations, and complications that are often excluded from controlled trials. At the same time, the modest number of CAR-T patients in the insurance cohort, just twelve individuals, highlights a limitation that readers should keep in mind: small samples can produce imprecise cost estimates, and the findings warrant confirmation in larger cohorts as CAR-T utilization expands.

For patients with diffuse large B-cell lymphoma whose disease has returned or resisted earlier lines of therapy, the choice between CAR-T and autologous stem cell transplantation is ultimately a clinical one, guided by disease characteristics, prior treatments, and patient fitness. But for the health systems that must pay for these choices, the new analysis offers a more complete accounting than has previously been available. If the downstream savings observed in the German data hold up as CAR-T use grows, the economic case for engineered immune cells may become considerably stronger, shifting the debate from whether societies can afford CAR-T therapy to how best to organize and reimburse the care that surrounds it.

Subject of Research: Comparative health-economic analysis of CAR-T cell therapy versus autologous stem cell transplantation for diffuse large B-cell lymphoma in Germany

Article Title: Comparative Cost and Utilization Analysis of CAR-T Therapy and Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma in Germany: Insights from Statutory Health Insurance Billing and Nationwide Inpatient Data

Article References: Froitzheim, A.-C., Kurte, M. S., Gehrke, K., Lempfert, S., Hesse, K., & Kron, F. (2026). Comparative Cost and Utilization Analysis of CAR-T Therapy and Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma in Germany: Insights from Statutory Health Insurance Billing and Nationwide Inpatient Data. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06628-0

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06628-0

Keywords: CAR-T therapy, diffuse large B-cell lymphoma, autologous stem cell transplantation, health economics, statutory health insurance, real-world data, inpatient costs, Germany, hematology, cell therapy, cost analysis, lymphoma treatment